30.47
price down icon1.55%   -0.48
after-market Handel nachbörslich: 30.47
loading
Schlusskurs vom Vortag:
$30.95
Offen:
$30.85
24-Stunden-Volumen:
601.85K
Relative Volume:
0.75
Marktkapitalisierung:
$2.85B
Einnahmen:
$4.72M
Nettoeinkommen (Verlust:
$-277.91M
KGV:
-8.1689
EPS:
-3.73
Netto-Cashflow:
$-203.56M
1W Leistung:
-4.27%
1M Leistung:
+1.03%
6M Leistung:
-21.16%
1J Leistung:
-43.13%
1-Tages-Spanne:
Value
$30.44
$31.48
1-Wochen-Bereich:
Value
$30.44
$33.28
52-Wochen-Spanne:
Value
$24.10
$62.53

Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile

Name
Firmenname
Crinetics Pharmaceuticals Inc
Name
Telefon
858-450-6464
Name
Adresse
6055 LUSK BLVD., SAN DIEGO, CA
Name
Mitarbeiter
437
Name
Twitter
@Crinetics
Name
Nächster Verdiensttermin
2024-11-12
Name
Neueste SEC-Einreichungen
Name
CRNX's Discussions on Twitter

Vergleichen Sie CRNX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CRNX
Crinetics Pharmaceuticals Inc
30.47 2.98B 4.72M -277.91M -203.56M -3.73
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-10 Eingeleitet Goldman Neutral
2025-03-25 Eingeleitet Stifel Buy
2025-02-11 Eingeleitet TD Cowen Buy
2025-02-04 Eingeleitet Wolfe Research Peer Perform
2025-01-22 Hochstufung Jefferies Hold → Buy
2024-03-06 Eingeleitet Citigroup Buy
2024-01-16 Eingeleitet Morgan Stanley Overweight
2023-12-21 Eingeleitet Jefferies Hold
2023-11-20 Fortgesetzt JP Morgan Overweight
2023-10-24 Fortgesetzt Cantor Fitzgerald Overweight
2023-08-31 Eingeleitet Oppenheimer Outperform
2023-04-24 Eingeleitet Piper Sandler Overweight
2023-03-30 Eingeleitet Robert W. Baird Outperform
2021-11-30 Eingeleitet JMP Securities Mkt Outperform
2021-11-23 Eingeleitet Evercore ISI Outperform
2021-06-18 Hochstufung JP Morgan Neutral → Overweight
2019-12-23 Eingeleitet ROTH Capital Buy
2019-02-14 Eingeleitet H.C. Wainwright Buy
2018-08-13 Eingeleitet JP Morgan Neutral
2018-08-13 Eingeleitet Leerink Partners Outperform
2018-08-13 Eingeleitet Piper Jaffray Overweight
Alle ansehen

Crinetics Pharmaceuticals Inc Aktie (CRNX) Neueste Nachrichten

pulisher
12:00 PM

What drives Crinetics Pharmaceuticals Inc. stock priceRapidly growing investment returns - jammulinksnews.com

12:00 PM
pulisher
Jul 22, 2025

What analysts say about Crinetics Pharmaceuticals Inc. stockStrong return on assets - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Crinetics’ TSHR antagonist demonstrates efficacy in thyroid autoimmune disorders - BioWorld MedTech

Jul 21, 2025
pulisher
Jul 21, 2025

Crinetics stock rating reiterated by Piper Sandler ahead of PALSONIFY PDUFA - Investing.com Canada

Jul 21, 2025
pulisher
Jul 21, 2025

H.C. Wainwright reiterates Buy rating on Crinetics stock at $81 price target - Investing.com UK

Jul 21, 2025
pulisher
Jul 21, 2025

Crinetics Pharmaceuticals’ Palsonify Gains Positive Endorsement for Acromegaly Treatment with Promising Pipeline Expansion - TipRanks

Jul 21, 2025
pulisher
Jul 21, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Purchased by Arizona State Retirement System - Defense World

Jul 21, 2025
pulisher
Jul 20, 2025

Is Crinetics Pharmaceuticals Inc. a good long term investmentPowerful growth strategies - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 20, 2025

The week in pharma: action, reaction and insight – week to July 18 - The Pharma Letter

Jul 20, 2025
pulisher
Jul 20, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Purchased by Xponance Inc. - Defense World

Jul 20, 2025
pulisher
Jul 19, 2025

Crinetics Pharmaceuticals Inc. Stock Analysis and ForecastHigh-velocity gains - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 19, 2025

Crinetics Pharmaceuticals (CRNX) Gets Initiated With a Hold Rating at Goldman Sachs - MSN

Jul 19, 2025
pulisher
Jul 18, 2025

Crinetics Pharmaceuticals’ SWOT analysis: promising pipeline drives stock outlook - Investing.com

Jul 18, 2025
pulisher
Jul 17, 2025

Crinetics stock maintains Buy rating at Jones Trading on positive ENDO’25 data - Investing.com Canada

Jul 17, 2025
pulisher
Jul 16, 2025

How Crinetics Pharmaceuticals Inc. stock performs during market volatilityFree Signals Group - Newser

Jul 16, 2025
pulisher
Jul 16, 2025

12 Oversold NASDAQ Stocks to Buy Now - Insider Monkey

Jul 16, 2025
pulisher
Jul 16, 2025

what makes crinetics pharmaceuticals inc. stock price move sharplySafer Investing With Bigger Upside - Newser

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Crinetics Pharmaceuticals Inc. stock price move sharplyFree Wealth-Building Investment Strategies - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Crinetics Pharmaceuticals Inc. stock attracts strong analyst attentionFree Investment Community - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

JMP reiterates Market Outperform rating on Crinetics stock as paltusotine shows strong data - Investing.com Nigeria

Jul 15, 2025
pulisher
Jul 15, 2025

Teacher Retirement System of Texas Sells 1,561 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Jul 15, 2025
pulisher
Jul 14, 2025

Crinetics Reports Durable Symptom, Hormone Control With Oral Drug In Acromegaly - inkl

Jul 14, 2025
pulisher
Jul 14, 2025

Crinetics reveals new data from acromegaly therapy programme - Yahoo Finance

Jul 14, 2025
pulisher
Jul 14, 2025

New data for oral acromegaly drug ahead of approval decision - The Pharma Letter

Jul 14, 2025
pulisher
Jul 14, 2025

Acromegaly's Next Frontier: Crinetics' PALSONIFY Aims to Overhaul Treatment Standards - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

Crinetics Pharmaceuticals New Data Show Durable Control of Palsonify in Acromegaly - MarketScreener

Jul 14, 2025
pulisher
Jul 13, 2025

CRNX to Highlight PALSONIFY Data at ENDO 2025 | CRNX Stock News - GuruFocus

Jul 13, 2025
pulisher
Jul 13, 2025

Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025 - The Manila Times

Jul 13, 2025
pulisher
Jul 13, 2025

Crinetics Pharmaceuticals Presents New Long-Term Data on PALSONIFY for Acromegaly at ENDO 2025 - Quiver Quantitative

Jul 13, 2025
pulisher
Jul 13, 2025

Breakthrough: Crinetics' Once-Daily Oral PALSONIFY Matches Injectable Treatments in 96-Week Acromegaly Study - Stock Titan

Jul 13, 2025
pulisher
Jul 13, 2025

Crinetics to Present New Long-Term Data Demonstrating Durable Co - GuruFocus

Jul 13, 2025
pulisher
Jul 12, 2025

Amalgamated Bank Boosts Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Jul 12, 2025
pulisher
Jul 12, 2025

The Goldman Sachs Group Initiates Coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX) - Defense World

Jul 12, 2025
pulisher
Jul 11, 2025

Crinetics Pharmaceuticals to Report Second Quarter 2025 Financia - GuruFocus

Jul 11, 2025
pulisher
Jul 11, 2025

Crinetics Earnings: Q2 2025 Results and Conference Call Scheduled for August 7 After Market Close - Stock Titan

Jul 11, 2025
pulisher
Jul 11, 2025

Goldman Sachs initiates coverage on Crinetics stock with Neutral rating By Investing.com - Investing.com Canada

Jul 11, 2025
pulisher
Jul 10, 2025

Crinetics Pharmaceuticals Announces July 2025 Inducement Grants - GuruFocus

Jul 10, 2025
pulisher
Jul 10, 2025

Crinetics Expands Team with 46 New Hires, Grants $3.2M+ in Equity Compensation - Stock Titan

Jul 10, 2025
pulisher
Jul 10, 2025

Goldman Sachs Initiates Crinetics Pharmaceuticals at Neutral With $36 Price Target - MarketScreener

Jul 10, 2025
pulisher
Jul 10, 2025

Goldman Sachs Begins Coverage of Crinetics (CRNX) with Neutral O - GuruFocus

Jul 10, 2025

Finanzdaten der Crinetics Pharmaceuticals Inc-Aktie (CRNX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):